Prediction Model for Identifying Computational Phenotypes of Children with Cerebral Palsy Needing Neurotoxin Treatments

Toxins (Basel). 2022 Dec 28;15(1):20. doi: 10.3390/toxins15010020.

Abstract

Factors associated with neurotoxin treatments in children with cerebral palsy (CP) are poorly studied. We developed and externally validated a prediction model to identify the prognostic phenotype of children with CP who require neurotoxin injections. We conducted a longitudinal, international, multicenter, double-blind descriptive study of 165 children with CP (mean age 16.5 ± 1.2 years, range 12−18 years) with and without neurotoxin treatments. We collected functional and clinical data from 2005 to 2020, entered them into the BTX-PredictMed machine-learning model, and followed the guidelines, “Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis”. In the univariate analysis, neuromuscular scoliosis (p = 0.0014), equines foot (p < 0.001) and type of etiology (prenatal > peri/postnatal causes, p = 0.05) were linked with neurotoxin treatments. In the multivariate analysis, upper limbs (p < 0.001) and trunk muscle tone disorders (p = 0.02), the presence of spasticity (p = 0.01), dystonia (p = 0.004), and hip dysplasia (p = 0.005) were strongly associated with neurotoxin injections; and the average accuracy, sensitivity, and specificity was 75%. These results have helped us identify, with good accuracy, the clinical features of prognostic phenotypes of subjects likely to require neurotoxin injections.

Keywords: cerebral palsy; neurotoxin treatment; prediction model.

Publication types

  • Randomized Controlled Trial
  • Multicenter Study

MeSH terms

  • Botulinum Toxins, Type A* / therapeutic use
  • Cerebral Palsy* / complications
  • Cerebral Palsy* / diagnosis
  • Cerebral Palsy* / drug therapy
  • Child
  • Double-Blind Method
  • Humans
  • Longitudinal Studies
  • Machine Learning
  • Muscle Spasticity / diagnosis
  • Muscle Spasticity / drug therapy
  • Neuromuscular Agents* / therapeutic use
  • Neurotoxins / therapeutic use
  • Prognosis

Substances

  • Botulinum Toxins, Type A
  • Neuromuscular Agents
  • Neurotoxins

Grants and funding

This research received no external funding.